Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative sintilimab plus chemotherapy with or without ipilimumab in resectable gastric or gastroesophageal junction adenocarcinoma
CTR20262571Phase 3Active
- Sponsor
- Innovent Biologics
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of sintilimab, ipilimumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Innovent Biologics. Started Jul 2026; status: active.
02
Drugs
sintilimabipilimumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20262571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262571.